ROWAN study overview
ROWAN will explore if there is a benefit of TheraSphere Y-90 Glass Microspheres with immunotherapy to improve response for HCC patients.
ROWAN will explore if there is a benefit of TheraSphere Y-90 Glass Microspheres with immunotherapy to improve response for HCC patients.
HCC
100 patients
Global study
Up to 50 sites
The ROWAN study is a global, open-label, multi-center, phase II, single-arm study to assess the efficacy of TheraSphere Y-90 Glass Microspheres followed by Durvalumab (Imfinzi®) with Tremelimumab (Imjudo®) (STRIDE regimen) in patients with hepatocellular carcinoma.
Caution: New Drug - Limited by Federal (or United States) law to investigational use.
Patients ≥ 18 years old of age with HCC who are not eligible for, or who have declined treatment with resection, ablation or liver transplant, will be considered for participation in this trial.
Patients will receive TheraSphere Y-90 treatment followed by a single dose of Tremelimumab in combination with Durvalumab which is given every 4 weeks to maximum of 18 months.
Assessment of the efficacy of TheraSphere followed by Durvalumab with Tremelimumab in HCC patients.
Complete response and partial response evaluated by mRECIST.
If you have questions about the ROWAN study and patient eligibility, please contact one of the principal investigators below.
City: Jacksonville, FL
Principal Investigator: Beau Toskich, MD
City: Washington, DC
Principal Investigator: Aiwu Ruth He, MD, PhD
For more information about the ROWAN study, please contact the clinical trial manager.
Patrice Feaster at patrice.feaster@bsci.com
TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation.